A multimarker approach for the prediction of coronary artery disease: Cost-effectiveness analysis

Value in Health

Volumn 13, Issue 6, 2010, Pages 770-777

  Lakić, Dragana ^a   Bogavac Stanojević, Nataša ^a   Jelić Ivanović, Zorana ^a   Kotur Stevuljević, Jelena ^a   Spasić, Slavica ^a   Kos, Mitja ^b  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

coronary artery disease; cost effectiveness; multimarker approach; risk prediction

Indexed keywords

ANTIOXIDANT; APOLIPOPROTEIN A; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; AUTACOID; BIOLOGICAL MARKER; C REACTIVE PROTEIN; LIPOPROTEIN A; MALONALDEHYDE; SUPEROXIDE; SUPEROXIDE DISMUTASE; THIOL DERIVATIVE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONEY; OXIDATIVE STRESS; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM;

EID: 77956360726     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2010.00769.x     Document Type: Article

References (44)

1. Mackay J, Mensah G. The Atlas of Heart Disease and Stroke. Geneva : WHO, 2004.
2. WHO Regional Office for Europe. European health for all database. Available from: http://data.euro.who.int/hfadb [Accessed June 5, 2009 J, Luengo-Fernandez R, Gray A, et al. Economic burden of cardiovascular disease in the enlarged European Union. Eur Heart J 2006 27 : 1610 1619.
3. Meisinger C, Loewel H, Mraz W, Koenig W. Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study. Eur Heart J 2005 26 : 271 278.
4. Wild SH, Fortmann SP, Marcovina SM. A prospective case-control study of lipoprotein levels and apo size and risk of coronary heart disease in Stanford Five-City Project participants. Arterioscler Thromb Vasc Biol 1997 17 : 239 245.
5. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein and the risk of myocardial infarction. JAMA 1993 270 : 2195 2199.
6. Koenig W, Sund M, Frohlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA Augsburg cohort study, 1984 to 1992. Circulation 1999 99 : 237 242.
7. Mendall MA, Strachen DP, Butland BK, et al. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J 2000 21 : 1584 1590.
8. Roivanen M, Viik-Kajander M, Palosuo P, et al. Infections, inflammation and the risk of coronary heart disease. Circulation 2000 101 : 252 257.
9. Biasucci LM. C-reactive protein and secondary prevention of coronary events. Clin Chim Acta 2001 311 : 49 52.
10. Zebrack JS, Anderson JL, Maycock CA, et al. Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infraction in patients with unstable or stable angina pectoris or acute myocardial infarction. Am J Cardiol 2002 89 : 145 149.
11. Kotur-Stevuljevic J, Memon L, Stefanovic A, et al. Correlation of oxidative stress parameters and inflammatory markers in coronary artery disease patients. Clin Biochem 2007 40 : 181 187.
12. Bridges AB, Scott NA, Pringle TH, et al. Relationship between the extent of coronary artery disease and indicators of free radical activity. Clin Cardiol 1992 15 : 169 174.
13. Landmesser U, Merten R, Spiekermann S, et al. Vascular extracellular superoxide dismutase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation 2000 101 : 2264 2270.
14. Harrison D, Griendling KK, Landmesser U, et al. Role of oxidative stress in atherosclerosis. Am J Cardiol 2003 91 : 7A 11A.
15. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006 355 : 2631 2639.
16. Morrow DA, Braunwald E. Future of biomarkers in acute coronary syndromes moving toward a multimarker strategy. Circulation 2003 108 : 250 252.
17. Grover SA, Coupal L, Hu XP. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work? JAMA 1995 274 : 801 806.
18. Lloyd-Jones D, Wilson PWF, Larson MG, et al. Framingham risk score and prediction of lifetime risk for coronary heart disease. Am J Cardiol 2004 94 : 20 4.
19. Brindle P, Beswick A, Fahey T, Ebrahim S. Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart 2006 92 : 1752 1759.
20. Ess SM, Syucs TD. Medical-economic aspect of high sensitivity C-reactive protein assay for the prediction of coronary heart disease. An analysis in Germany and Italy. Ital Heart J 2001 2 : 181 188.
21. Blake GJ, Ridker PM, Kuntz KM. Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia. Am J Med 2003 114 : 485 494.
22. Bogavac-Stanojevic N, Petrova G, Jelic-Ivanovic Z, et al. Cost-effectiveness analysis in diagnosis of coronary artery disease: choice of laboratory markers. Clin Biochem 2007 40 : 1180 1187.
23. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972 18 : 499 502.
24. Girotti MJ, Khan N, McLellan BA. Early measurement of systemic lipid peroxidation products in plasma of major blunt trauma patients. J Trauma 1991 31 : 32 5.
25. Auclair C, Voisin E. Nitroblue tetrazolium reduction. In : Greenwald RA, ed., CRC Handbook of Methods for Oxygen Radical Research. Boca Raton, FL : CRC Press, 1985.
26. Misra HP, Fridovich I. The role of superoxide anion in the autooxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 1972 247 : 3170 3175.
27. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1952 82 : 70 7.
28. RIHI. Codes and price list RIHI [in Serbian]. Available from: http://212.200.153.156/nextelfak/ [Accessed December 2, 2010 MT, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes (2nd ed.). New York : Oxford University Press, 1997.
29. Hosmer DW, Lemeshow S. Assessing the Fit of the Model. Applied Logistic Regression. New York : John Wiley and Sons, 2000.
30. Efron B, Gong G. A leisurely look at the bootstrap, the jackknife and cross-validation. Am Stat 1983 37 : 36 48.
31. Elliot R, Payne K. Essentials of Economic Evaluation in Healthcare. London : Pharmaceutical Press, 2005 : 104-10.
32. Zweig MH, Cambell G. Receiver-operating characteristics (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993 39 : 561 577.
33. Koenig W, Löwel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham score. Implications for future risk assessment: results from a large cohort study in Southern Germany. Circulation 2004 109 : 1349 1353.
34. Balla B, Mocak J, Pivovarnikova H, Balla J. Comparative study of cardiovascular markers data by various techniques of multivariate analysis. Chemom Intell Lab Sys 2004 72 : 256 267.
35. Schnell-Inderst P, Schwarzer R, Gohler A, et al. Prognostic value, clinical effectiveness, and cost-effectiveness of high-sensitivity C-reactive protein as a marker for major cardiac events in asymptomatic individuals. Int J Technol Assess Health Care 2010 26 : 30 9.
36. Jelic-Ivanovic Z, Bujisic N, Spasic S, et al. Circulating sTWEAK improves the prediction of coronary artery disease. Clin Biochem 2009 42 : 1381 1386.
37. Stefanović A, Kotur-Stevuljević J, Spasić S, et al. Association of oxidative stress and paraoxonase status with PROCAM risk score. Clin Biochem 2009 42 : 617 623.
38. Miller JM, Rochitte CE, Dewey M, et al. Diagnostic performance of coronary angiography by 64-row CT. N Engl J Med 2008 359 : 2324 2336.
39. Vassan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006 113 : 2335 2362.
40. Ridker PM, Brown NJ, Vaughan DE, et al. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 2004 109 : IV-6 19.
41. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002 347 : 1557 1565.
42. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009 119 : e21 181.
43. Allender S, Scarborough P, Peto V, et al. European cardiovascular disease statistic, 2008 edition. Available from: http://www.heartstats.org/datapage. asp?id=7683 [Accessed June 30, 2010 JK, Gilmore A, Budoff MJ, et al. Cost-effectiveness of coronary CT angiography versus myocardial perfusion SPECT for evaluation of patients with chest pain and no known coronary artery disease. Radiology 2010 254 : 801 808.
44. Rutjes AW, Reitsma JB, Coomarasamy A, et al. Evaluation of diagnostic tests when there is no gold standard. A review of methods. Health Technol Assess 2007 11 : 1 51.